DICERNA PHARMACEUTICALS, INC.

(DRNA)
SummaryQuotesChartsNewsRatingsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chardan Downgrades Dicerna Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $38.25 From $28 on Pending Acquisition

12/09/2021 | 06:32am EDT


© MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
2021Dicerna Pharmaceuticals Coverage Dropped by Chardan After Novo Nordisk Closes Acquisiti..
MT
2021Chardan Drops Coverage on Neutral-Rated Dicerna Pharmaceuticals on Acquisition by Novo ..
MT
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P TMI Index
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Biotechnology Select Industr..
CI
2021DICERNA PHARMACEUTICALS, INC.(NASDAQ : DRNA) dropped from S&P Global BMI Index
CI
2021Novo Nordisk Completes Dicerna Pharmaceuticals Acquisition
MT
2021DICERNA PHARMACEUTICALS : Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acq..
PU
2021DICERNA PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice o..
AQ
2021Novo Nordisk Closes on $3.3 Billion Acquisition of Dicerna Pharmaceuticals
MT
2021Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
BU
More news
Analyst Recommendations on DICERNA PHARMACEUTICALS, INC.
More recommendations
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | DRNA | US2530311081 | MarketScreener
Managers and Directors
Bob D. Brown President
Shreeram Aradhye Chief Medical Officer & Executive Vice President
James B. Weissman Chief Operating Officer & Executive Vice President
Jamie Haney Director
Ulrich Christian Otte Director
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.0.00%2 986
GILEAD SCIENCES, INC.-12.86%79 298
REGENERON PHARMACEUTICALS, INC.4.06%71 026
VERTEX PHARMACEUTICALS16.33%64 540
WUXI APPTEC CO., LTD.-19.12%41 409
BIONTECH SE-39.08%38 169